Rigel Pharmaceuticals, Inc. (RIGL)
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL)
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
Rigel Pharmaceuticals is a commercial-stage biotech growing revenue with three marketed drugs and a promising pipeline. RIGL's product sales grew 72% YoY in 1H FY2025, with diversification reducing reliance on TAVALISSE and GAVRETO showing strong adoption. On FY2025 revenue projections, Rigel trades at ~2.8x forward EV/sales; valuing the company in line with the sector median implies a share price of approximately $63.
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.
What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Overlooked Stock: RIGL Nearly Doubles Stock in August
Rigel Pharmaceuticals (RIGL) is up 88% in August and more than tripled its stock price over the last year. The staggering upside rally began with a massive earnings beat and raised guidance.
Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout
Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, expecting positive net income and robust sales growth, signaling Rigel's transition to a self-sustaining, growth-focused biotech. Pipeline progress, especially with R289 and REZLIDHIA label expansion, offers long-term catalysts, but investors must weigh risks from nonrecurring revenue and clinical execution.
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Rigel Pharmaceuticals, Inc. (RIGL) is looking like an interesting pick, as it just reached a key level of support. RIGL's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
